NMO-IgG predicts the outcome of recurrent optic neuritis

Neurology

Volumn 70, Issue 23, 2008, Pages 2197-2200

  Matiello, M ^a   Lennon, V A ^a   Jacob, A ^a   Pittock, S J ^a   Lucchinetti, C F ^a   Wingerchuk, D M ^b   Weinshenker, B G ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; NEUROMYELITIS OPTICA IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; VISUAL ACUITY; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; NEUROMYELITIS OPTICA; OPTIC NEURITIS; PREDICTIVE VALUE OF TESTS; RECURRENCE; TREATMENT OUTCOME;

EID: 44949174179     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000303817.82134.da     Document Type: Article

References (16)

1. Pirko I, Blauwet LK, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Arch Neurol 2004;61:1401-1405.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
3. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51:1219-1220.
4. Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist 2007;13:2-11.
5. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007;252:57-61.
6. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007;13:256-259.
7. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477.
8. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
9. Saiz A, Zuliani L, Blanco Y, et al. Revised diagnostic criteria for neuromyelitis optica (NMO): Application in a series of suspected patients. J Neurol 2007;254: 1233-1237.
10. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-569.
11. Wingerchuk DM, Hogancamp WF, O'Brien PC, Wein-shenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
12. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
13. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007;114:810-815.
14. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007;68:1076-1077.
15. Scott TF, Kassab SL, Pittock SJ. Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol 2006;63:1398-1400.
16. Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007; 130:1206-1223.